Revenues for the three months ended December 31, 2012 were $5.2 million compared to $5.0 million for the same period in 2011. For the year ended December 31, 2012, revenues were $27.2 million compared to $41.0 million for the same period in 2011. The decrease in revenues during the year ended December 31, 2012 was due to the $25.0 million upfront payment received from Bayer in 2011. Excluding this one-time payment, revenues for the year ended December 31, 2012 increased $11.2 million primarily due to sponsored development activities and milestone payments from our collaboration with Bayer.
Research and development expenses for the three months ended December 31, 2012 were $16.5 million compared to $13.8 million for the same period in 2011. For the year ended December 31, 2012 and 2011, research and development expenses were $69.0 million and $49.5 million, respectively. The increase in research and development expenses was primarily related to higher clinical trial and development costs for tedizolid phosphate.
General and administrative expenses for the three months ended December 31, 2012 increased to $4.7 million compared to $2.8 million for the same period in 2011. For the years ended December 31, 2012 and 2011, general and administrative expenses were $15.4 million and $11.3 million, respectively. The increase in general and administrative expenses was primarily due to an increase in commercial planning activities in 2012.
As of March 1, 2013, Trius had 47,854,151 shares outstanding.Program Updates & Upcoming Events In December 2012, Trius completed enrollment of its ESTABLISH 2 study, the second Phase 3 trial in acute bacterial skin and skin structure infections, or ABSSSI. The study remains on track to report top line data near the end of the first quarter in 2013. In 2012 and early 2013, Trius also completed additional clinical trials needed to support its planned New Drug Application (NDA) filing. If the ESTABLISH 2 study endpoints are met, Trius plans to file its NDA during the second half of 2013.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV